Cytek Biosciences, Inc.

Name: Cytek Biosciences, Inc. standardized financial statements, quarterly
Creator: Listed

CTKBNasdaqCIK 1831915TechnologyFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$48.1m, Q2 FY2026

Operating income−$11.4m, Q2 FY2026

Net income−$12.2m, Q2 FY2026

Cytek Biosciences, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	48.0	58.2	44.9	46.6	51.5	57.5	41.5	45.6	52.3	62.1	44.1	48.1
Cost of revenue	$m	20.8	25.2	21.8	21.2	22.5	23.8	21.3	21.7	24.7	29.3	22.9	19.8
Gross profit	$m	27.2	33.0	23.0	25.4	29.0	33.7	20.2	23.9	27.6	32.9	21.3	28.3
Research and development	$m	11.2	10.9	9.8	10.0	9.9	9.7	9.7	8.8	9.0	9.0	9.6	9.7
Operating income	$m	(6.4)	(0.1)	(10.7)	(8.5)	(4.2)	3.0	(15.0)	(10.6)	(9.2)	(5.6)	(18.5)	(11.4)
Interest expense	$m	0.6	0.4	0.4	0.1	0.1	(5.9)	0.3	0.4	0.5	(0.7)	0.3	0.3
Income tax	$m	2.3	(1.4)	(2.8)	3.2	(0.8)	0.7	0.1	(1.2)	(2.3)	40.0	1.5	0.5
Net income	$m	(6.5)	5.5	(6.2)	(10.4)	0.9	9.6	(11.4)	(5.6)	(5.5)	(44.1)	(18.9)	(12.2)
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Basic EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Balance sheet

Cash and equivalents$73.8m, Q2 FY2026

Shareholders' equity$322.0m, Q2 FY2026

Cytek Biosciences, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	164	167	169	178	162	98.7	95.3	75.5	93.3	90.9	65.7	73.8
Current assets	$m	422	392	389	384	390	396	381	383	388	392	379	378
Total assets	$m	519	494	492	484	491	500	483	493	495	462	449	447
Current liabilities	$m	58.7	56.2	55.6	52.4	62.8	67.7	67.7	73.3	75.2	77.8	80.9	84.3
Total liabilities	$m	104	101	99.5	94.6	106	104	103	116	116	120	121	125
Shareholders' equity	$m	416	393	393	389	385	396	380	378	379	342	328	322

Cash flow

Operating cash flow$1.4m, Q2 FY2026

Capital expenditure$2.2m, Q2 FY2026

Share repurchases$0, Q2 FY2026

Cytek Biosciences, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(4.2)	9.5	4.0	6.2	13.2	2.0	(0.1)	0.1	(3.9)	(0.8)	(2.7)	1.4
Capital expenditure	$m	1.3	1.5	0.6	1.1	1.0	0.9	0.8	1.6	0.7	1.0	2.2	2.2
Share repurchases	$m	not reported	34.6	0.0	2.7	11.9	7.0	10.6	4.5	(0.0)	(0.0)	0.0	0.0

Diluted shares (weighted)129.46m, Q2 FY2026

Cytek Biosciences, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	139	135	136	136	131	131	133	128	127	128	129	129

Shares outstanding: 129.98m at Jul 31, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.